Sign In
Buy BNIGF
$0.0021
+0 (+0%)
At Close: Jun 02, 2026
Beroni Initiates Manufacture of its Novel, Potential Anti-Cancer Drug PENAO
08:30am, Wednesday, 18'th Aug 2021
NEW YORK and SYDNEY, Australia, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni”), an Australia-based diversified biopharmaceutical enterprise, announced that PENA
Beroni Group Issues US$2 Million of Convertible Notes to Fund Research and Development Plans
08:30am, Friday, 28'th May 2021
NEW YORK and SYDNEY, Australia, May 28, 2021 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based diversified biopharmaceutical enterprise
Beroni Group's SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) Has Received Export Permit
08:30am, Tuesday, 27'th Apr 2021
NEW YORK and SYDNEY, Australia, April 27, 2021 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based diversified biopharmaceutical enterpris
Beroni Acquires Majority Interest in PENAO, an Anti-Cancer Drug Development Company
08:30am, Wednesday, 03'rd Feb 2021
NEW YORK and SYDNEY, Australia, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni”), an Australia-based diversified biopharmaceutical enterprise today announces tha
